{"schema_version":"secwatch.filing_event.v1","accession":"0001551306-23-000060","form_type":"8-K","ticker":"PGNY","cik":"0001551306","company_name":"Progyny, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.272397+00:00","generated_at":"2026-06-12T08:09:15.571051+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Progyny Q2 revenue $279.4M (+43% YoY); raises full-year guidance","bullets":["Revenue $279.4M (+43% YoY); net income $15.0M ($0.15 diluted EPS) vs $8.8M ($0.09) YoY.","Adjusted EBITDA $47.5M (+44% YoY); record operating cash flow $76.0M, helped by new pharmacy partner agreements.","Clients grew to 384 (from 273); ART cycles 14,771 (+42% YoY); utilization rates improved.","FY 2023 revenue guidance raised to $1,075-1,090M (37-39% growth); adj EBITDA guided $183-187.5M.","Q3 2023 revenue guided $268-273M; adj EBITDA $44.7-46.2M."],"urls":{"canonical":"https://secwatch.observer/filing/0001551306-23-000060","json":"https://secwatch.observer/filing/0001551306-23-000060.json","markdown":"https://secwatch.observer/filing/0001551306-23-000060.md","text":"https://secwatch.observer/filing/0001551306-23-000060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551306/000155130623000060/0001551306-23-000060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551306/000155130623000060/pgny-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T08:09:15.571051+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4df25e274c6cc144305b7c8a55b5a0c7df6df9a7","claim":"Progyny, Inc. reported three-month period ended June 30, 2023 results: revenue $279,373, net income $14,991, EPS $0.15. Guidance raised.","evidence_excerpt":"quarter,” said Mark Livingston, Progyny’s Chief Financial Officer. Second Quarter 2023 Highlights: (unaudited; in thousands, except per share amounts) 2Q 2023 2Q 2022 Revenue $279,373 $195,004 Gross Profit $60,641 $43,887 Gross Margin 21.7% 22.5% Net Income $14,991 $8,768 Net Income per Diluted Share 1 $0.15 $0.09 Adjusted EBITDA 2 $47,464 $32,878 Adjusted","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551306/000155130623000060/0001551306-23-000060-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three-month period ended June 30, 2023"},{"label":"Revenue","value":"$279,373"},{"label":"Net income","value":"$14,991"},{"label":"EPS","value":"$0.15"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}